JP2016511260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511260A5 JP2016511260A5 JP2015560380A JP2015560380A JP2016511260A5 JP 2016511260 A5 JP2016511260 A5 JP 2016511260A5 JP 2015560380 A JP2015560380 A JP 2015560380A JP 2015560380 A JP2015560380 A JP 2015560380A JP 2016511260 A5 JP2016511260 A5 JP 2016511260A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- mitochondrial
- peptide
- gene mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 206010064571 Gene mutation Diseases 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000012268 mitochondrial disease Diseases 0.000 claims description 10
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 claims description 10
- 210000003205 muscle Anatomy 0.000 claims description 8
- 201000001119 neuropathy Diseases 0.000 claims description 8
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 230000007823 neuropathy Effects 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims description 6
- 206010003591 Ataxia Diseases 0.000 claims description 6
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims description 6
- 230000002438 mitochondrial effect Effects 0.000 claims description 6
- 230000000750 progressive effect Effects 0.000 claims description 6
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 206010033799 Paralysis Diseases 0.000 claims description 5
- 101150081019 surf1 gene Proteins 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 208000000044 Amnesia Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims description 3
- 206010008748 Chorea Diseases 0.000 claims description 3
- 206010010774 Constipation Diseases 0.000 claims description 3
- 102000016903 DNA Polymerase gamma Human genes 0.000 claims description 3
- 108010014080 DNA Polymerase gamma Proteins 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010012559 Developmental delay Diseases 0.000 claims description 3
- 208000014094 Dystonic disease Diseases 0.000 claims description 3
- 102000015782 Electron Transport Complex III Human genes 0.000 claims description 3
- 108010024882 Electron Transport Complex III Proteins 0.000 claims description 3
- 208000013016 Hypoglycemia Diseases 0.000 claims description 3
- 208000020358 Learning disease Diseases 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 208000007101 Muscle Cramp Diseases 0.000 claims description 3
- 208000010428 Muscle Weakness Diseases 0.000 claims description 3
- 206010028372 Muscular weakness Diseases 0.000 claims description 3
- 208000005392 Spasm Diseases 0.000 claims description 3
- 206010044565 Tremor Diseases 0.000 claims description 3
- 230000001919 adrenal effect Effects 0.000 claims description 3
- 208000008784 apnea Diseases 0.000 claims description 3
- 208000029560 autism spectrum disease Diseases 0.000 claims description 3
- 208000012601 choreatic disease Diseases 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000010118 dystonia Diseases 0.000 claims description 3
- 208000028329 epileptic seizure Diseases 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000006443 lactic acidosis Diseases 0.000 claims description 3
- 201000003723 learning disability Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 230000006984 memory degeneration Effects 0.000 claims description 3
- 208000023060 memory loss Diseases 0.000 claims description 3
- 230000003340 mental effect Effects 0.000 claims description 3
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 230000035807 sensation Effects 0.000 claims description 3
- 230000009747 swallowing Effects 0.000 claims description 3
- 230000006016 thyroid dysfunction Effects 0.000 claims description 3
- 208000024806 Brain atrophy Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 17
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000010627 oxidative phosphorylation Effects 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 230000006378 damage Effects 0.000 description 3
- -1 Complex IV Proteins 0.000 description 2
- 208000012239 Developmental disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 206010016165 failure to thrive Diseases 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 208000006136 Leigh Disease Diseases 0.000 description 1
- 208000017507 Leigh syndrome Diseases 0.000 description 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 1
- 102000046669 Surf-1 Human genes 0.000 description 1
- 108060007963 Surf-1 Proteins 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771642P | 2013-03-01 | 2013-03-01 | |
| US201361771534P | 2013-03-01 | 2013-03-01 | |
| US61/771,642 | 2013-03-01 | ||
| US61/771,534 | 2013-03-01 | ||
| PCT/US2014/019645 WO2014134562A1 (en) | 2013-03-01 | 2014-02-28 | Methods for the treatment of mitochondrial disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019133638A Division JP2019214580A (ja) | 2013-03-01 | 2019-07-19 | ミトコンドリア疾患の治療のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511260A JP2016511260A (ja) | 2016-04-14 |
| JP2016511260A5 true JP2016511260A5 (cg-RX-API-DMAC7.html) | 2017-04-06 |
| JP6839490B2 JP6839490B2 (ja) | 2021-03-10 |
Family
ID=51428871
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560380A Active JP6839490B2 (ja) | 2013-03-01 | 2014-02-28 | ミトコンドリア疾患の治療のための方法 |
| JP2019133638A Pending JP2019214580A (ja) | 2013-03-01 | 2019-07-19 | ミトコンドリア疾患の治療のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019133638A Pending JP2019214580A (ja) | 2013-03-01 | 2019-07-19 | ミトコンドリア疾患の治療のための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10793597B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3673913A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6839490B2 (cg-RX-API-DMAC7.html) |
| CN (5) | CN116474071A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2916884C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2961378T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2755134T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE046596T2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014134562A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107312066A (zh) * | 2011-12-09 | 2017-11-03 | 康德生物医疗技术公司 | 芳香族阳离子肽及其用途 |
| DK2961378T3 (da) * | 2013-03-01 | 2019-11-25 | Stealth Biotherapeutics Corp | Fremgangsmåder til behandlingen af mitochondrisk sygdom |
| EP3626252A1 (en) | 2013-03-01 | 2020-03-25 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| CA2916977A1 (en) | 2013-06-26 | 2014-12-31 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| EP3501532A3 (en) * | 2014-05-28 | 2019-07-17 | Stealth BioTherapeutics Corp | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof |
| WO2017156403A1 (en) * | 2016-03-11 | 2017-09-14 | Stealth Biotherapeutics | Crystalline salt forms |
| WO2017180535A1 (en) | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| EP4000690A1 (en) * | 2016-05-19 | 2022-05-25 | Stealth BioTherapeutics Inc. | Compositions and methods for the prevention and treatment of mitochondrial myopathies |
| IL322723A (en) | 2017-04-05 | 2025-10-01 | Stealth Biotherapeutics Inc | Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| US20210382071A1 (en) * | 2018-10-10 | 2021-12-09 | Helsingin Yliopisto | Biomarkers for mitochondrial diseases and related methods |
| WO2020214518A1 (en) * | 2019-04-18 | 2020-10-22 | Arcuate Therapeutics, Inc. | Methods of treating renal conditions using peptides that improve mitochondrial function |
| JP2023541403A (ja) * | 2020-09-09 | 2023-10-02 | ソーシャル・プロフィット・ネットワーク | ビオチンをミトコンドリアに送達するための方法及び組成物 |
| US12116382B2 (en) | 2022-11-28 | 2024-10-15 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine analogs |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| EP1423501A4 (en) * | 2001-08-06 | 2008-08-06 | Univ Vanderbilt | DEVICE AND METHOD FOR MEASURING THE RESPONSE OF AT LEAST ONE CELL TO A MEDIUM |
| BRPI0105509B8 (pt) | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga |
| CN101440124B (zh) * | 2003-02-04 | 2012-07-18 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
| PT1599216E (pt) * | 2003-02-04 | 2013-12-17 | Cornell Res Foundation Inc | Métodos de prevenção da transição de permeabilidade mitocondrial |
| US20070135335A1 (en) | 2003-02-10 | 2007-06-14 | Autogen Research Pty Ltd. | Therapeutic molecules |
| WO2005023274A1 (en) * | 2003-09-05 | 2005-03-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium |
| CA2971931C (en) * | 2004-01-23 | 2019-01-08 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| US8500720B2 (en) | 2005-05-09 | 2013-08-06 | Medtronic, Inc | Method and apparatus for treatment of cardiac disorders |
| US20070265216A1 (en) | 2005-10-05 | 2007-11-15 | Gross Richard W | Enhanced medical treatment in diabetic cardiomyopathy |
| AU2007237899A1 (en) | 2006-04-18 | 2007-10-25 | Cortendo Invest, Ab | Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions |
| CA2688125A1 (en) * | 2007-05-02 | 2008-11-13 | The Mclean Hospital Corporation | Methods and compositions for mitochondrial replacement therapy |
| US20080318909A1 (en) | 2007-06-14 | 2008-12-25 | Sparagna Genevieve C | Use Of Linoleic Compounds Against Heart Failure |
| WO2008156654A2 (en) | 2007-06-15 | 2008-12-24 | Massachusetts Institute Of Technology | Cytoskeleton modulators for treating metabolic disorders |
| CN101951936A (zh) * | 2008-02-26 | 2011-01-19 | 康奈尔大学 | 用于防止和治疗急性肾损伤的方法 |
| US20110197294A1 (en) | 2008-06-04 | 2011-08-11 | Gottlieb Roberta A | Compositions and methods for restoring mitochondrial electron transfer function |
| CN104231070B (zh) | 2008-08-07 | 2017-09-01 | 益普生制药股份有限公司 | N‑端修饰的葡萄糖依赖性促胰岛素多肽（gip）类似物 |
| CN102573881A (zh) | 2009-03-20 | 2012-07-11 | 通用医疗公司以马萨诸塞州通用医疗公司名义经营 | 预防和治疗烧伤损伤和继发性并发症的方法 |
| WO2010121268A2 (en) * | 2009-04-17 | 2010-10-21 | The Salk Institute For Biological Studies | Regulation of aging by modulation of mitochondrial function |
| WO2010132347A2 (en) | 2009-05-11 | 2010-11-18 | University Of Maryland, Baltimore | Docosahexaenoic acid for the treatment of heart failure |
| JP5909182B2 (ja) | 2009-08-12 | 2016-04-26 | コーネル ユニヴァーシティー | 代謝性症候群を予防し又は治療するための方法 |
| EP3338788A1 (en) * | 2009-08-24 | 2018-06-27 | Stealth Peptides International, Inc. | Methods and copositions for preventing or treating opthalmic conditions |
| CN102711785A (zh) | 2009-10-05 | 2012-10-03 | 康奈尔大学 | 预防或治疗心力衰竭的方法 |
| US8719939B2 (en) | 2009-12-31 | 2014-05-06 | Mcafee, Inc. | Malware detection via reputation system |
| EP3090754A1 (en) | 2009-12-31 | 2016-11-09 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
| CA2797644A1 (en) | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| JP4643749B1 (ja) | 2010-02-03 | 2011-03-02 | 昭和電工株式会社 | 表面被覆サーメット部材の耐酸化膜形成用の処理液 |
| US20130040901A1 (en) | 2010-02-26 | 2013-02-14 | University Of Florida Research Foundation Inc. | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| EP3040080A1 (en) | 2010-03-15 | 2016-07-06 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| EP2942354A1 (en) | 2010-05-03 | 2015-11-11 | Stealth Peptides International, Inc. | Aromatic-Cationic Peptides and Uses of Same |
| US20130288985A1 (en) * | 2010-07-15 | 2013-10-31 | The Schepens Eye Research Institute Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| CA2807507A1 (en) * | 2010-08-06 | 2012-02-09 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with naphthoquinones |
| JP2013538799A (ja) * | 2010-08-06 | 2013-10-17 | アンペア ライフ サイエンシーズ，インコーポレイテッド | ビタミンｋを用いたミトコンドリア病の処置 |
| US9241933B2 (en) * | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| WO2012129427A2 (en) * | 2011-03-24 | 2012-09-27 | Cornell University | Aromatic-cationic peptides and uses of same |
| JP6157481B2 (ja) | 2011-09-29 | 2017-07-05 | メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ | 芳香族陽イオン性ペプチドおよびその使用方法 |
| CN104114181B (zh) * | 2011-10-17 | 2017-06-09 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
| AU2012325723A1 (en) | 2011-10-21 | 2014-05-15 | Stemgenics, Inc | Functionalized nanoparticles for intracellular delivery of biologically active molecules |
| CA2865317A1 (en) * | 2012-02-22 | 2013-08-29 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
| WO2013126775A1 (en) * | 2012-02-23 | 2013-08-29 | Cornell University | Aromatic-cationic peptides and uses of same |
| US20150266946A1 (en) * | 2012-10-09 | 2015-09-24 | President And Fellows Of Harvard College | Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function |
| CN110193077A (zh) | 2012-10-22 | 2019-09-03 | 康德生物医疗技术公司 | 降低与心脏衰竭相关的风险和与其相关的因素的方法 |
| DK2961378T3 (da) * | 2013-03-01 | 2019-11-25 | Stealth Biotherapeutics Corp | Fremgangsmåder til behandlingen af mitochondrisk sygdom |
| EP3626252A1 (en) | 2013-03-01 | 2020-03-25 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| CA2916977A1 (en) | 2013-06-26 | 2014-12-31 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
-
2014
- 2014-02-28 DK DK14757000T patent/DK2961378T3/da active
- 2014-02-28 JP JP2015560380A patent/JP6839490B2/ja active Active
- 2014-02-28 US US14/771,411 patent/US10793597B2/en active Active
- 2014-02-28 CA CA2916884A patent/CA2916884C/en active Active
- 2014-02-28 CN CN202310407669.1A patent/CN116474071A/zh active Pending
- 2014-02-28 CN CN201480022764.9A patent/CN105517533A/zh active Pending
- 2014-02-28 ES ES14757000T patent/ES2755134T3/es active Active
- 2014-02-28 WO PCT/US2014/019645 patent/WO2014134562A1/en not_active Ceased
- 2014-02-28 CN CN202311795418.1A patent/CN117752766A/zh active Pending
- 2014-02-28 CN CN202310408404.3A patent/CN116440247A/zh active Pending
- 2014-02-28 HU HUE14757000A patent/HUE046596T2/hu unknown
- 2014-02-28 EP EP19199765.9A patent/EP3673913A1/en active Pending
- 2014-02-28 CN CN201910589605.1A patent/CN110339339A/zh active Pending
- 2014-02-28 EP EP14757000.6A patent/EP2961378B1/en active Active
-
2019
- 2019-07-19 JP JP2019133638A patent/JP2019214580A/ja active Pending
-
2020
- 2020-07-15 US US16/930,028 patent/US20200407396A1/en not_active Abandoned
-
2022
- 2022-10-11 US US17/963,697 patent/US20230279051A1/en active Pending
-
2024
- 2024-09-19 US US18/890,079 patent/US20250109167A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016511260A5 (cg-RX-API-DMAC7.html) | ||
| JP2019507781A5 (cg-RX-API-DMAC7.html) | ||
| JP2014527040A5 (cg-RX-API-DMAC7.html) | ||
| JP2009533359A (ja) | 神経障害性疼痛を治療するためのイミダゾ［２，１−ｂ］−１，３，４−チアジアゾール−２−スルホンアミド化合物の使用 | |
| CN108289932A (zh) | 胞外dna作为神经变性的治疗靶点 | |
| EA200801764A1 (ru) | Арилвинилазациклоалкановые соединения и способы их получения и применения | |
| JP2015512420A5 (cg-RX-API-DMAC7.html) | ||
| EP2642989A1 (en) | Methods of treating eye diseases associated with inflammation and vascular proliferation | |
| JP2014511365A5 (cg-RX-API-DMAC7.html) | ||
| CN109350616B (zh) | I-brd9或其衍生物在制备抗癫痫药物中的应用 | |
| JP2017508737A5 (cg-RX-API-DMAC7.html) | ||
| Hashim et al. | Early cyclosporine treatment of incipient toxic epidermal necrolysis induced by concomitant use of lamotrigine and sodium valproate | |
| Carney et al. | The long-term maintenance treatment of schizophrenic out-patients with depot flupenthixol | |
| JP5745526B2 (ja) | 糖尿病の予防のためのスルホンアミド | |
| JP2020527172A5 (cg-RX-API-DMAC7.html) | ||
| US9968585B2 (en) | Prevention or treatment agent for cerebral amyloid beta storage diseases | |
| JP2011509257A5 (cg-RX-API-DMAC7.html) | ||
| TWI643617B (zh) | ２－（５ｓ－甲基－２－氧－４ｒ－苯基－吡咯烷－１－基）－乙酰胺用於製備治療或預防疾病發作之藥物的用途 | |
| X Hoang et al. | Treating asthma as a neuroelectrical disorder | |
| JP6298490B2 (ja) | エリスロポエチン及びセフトリアキソンを含有する組成物並びにそのパーキンソン認知症を治療するための用途 | |
| Samanta et al. | Amikacin-triggered anaphylaxis: Should we go for skin test? | |
| US20200181069A1 (en) | Substituted bisphenylalkylurea compounds and methods | |
| CN1756728A (zh) | 2－(丁基－1－磺酰氨基)－n－[1(r)－(6－甲氧基吡啶－3－基)丙基 ]苯甲酰胺、其作为药物的用途以及包含所述化合物的药物制剂 | |
| JP5947041B2 (ja) | 安全なｉｌ−１７産生抑制剤 | |
| JP2019023235A (ja) | アミロイド線維形成の抑制又は阻害剤 |